Literature DB >> 28513835

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.

C H Smith1, Z K Jabbar-Lopez1, Z Z Yiu2, T Bale3, A D Burden4, L C Coates5,6, M Cruickshank7, T Hadoke8, E MacMahon9, R Murphy10, C Nelson-Piercy11, C M Owen12, R Parslew13, E Peleva1, E Pottinger7, E J Samarasekera7, J Stoddart14, C Strudwicke8, V A Venning15, R B Warren2, L S Exton16, M F Mohd Mustapa16.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28513835     DOI： 10.1111/bjd.15665

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  44 in total

1.  Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database

Authors:  Megan H. Noe; Daniel B. Shin; Jalpa A. Doshi; David J. Margolis; Joel M. Gelfand
Journal:  J Drugs Dermatol       Date:  2019-08-01       Impact factor: 2.114

2.  Systemic agents for psoriasis and their relevance to primary care.

Authors:  Simon Tso; William Hunt; Helen Frow; Andrew Ilchyshyn
Journal:  Br J Gen Pract       Date:  2019-02       Impact factor: 5.386

3.  Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.

Authors:  J A Walsh; A B Gottlieb; B Hoepken; T Nurminen; P J Mease
Journal:  Clin Rheumatol       Date:  2018-09-06       Impact factor: 2.980

Review 4.  Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.

Authors:  Carolyn Jean Chua-Aguilera; Burkhard Möller; Nikhil Yawalkar
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

5.  The Presence of HLA-A Bw4-80I KIR Ligands Could Predict "Difficult-to-Treat" Psoriasis and Poor Response to Etanercept.

Authors:  M Guarene; A Pasi; V Bolcato; R Cananzi; A Piccolo; I Sbarsi; C Klersy; R Cacciatore; Valeria Brazzelli
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

6.  T cells and cytokines in inflamed psoriatic skin. Who's in charge?

Authors:  Simon Milling; Stefan Siebert
Journal:  Immunology       Date:  2020-08       Impact factor: 7.397

7.  Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom.

Authors:  Junko Takeshita; Daniel B Shin; Alexis Ogdie; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2018-03-02       Impact factor: 8.551

8.  Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.

Authors:  Sarah Patterson; Gabriela Schmajuk; Michael Evans; Ishita Aggarwal; Zara Izadi; Milena Gianfrancesco; Jinoos Yazdany
Journal:  Jt Comm J Qual Patient Saf       Date:  2019-01-25

Review 9.  Psoriasis and Treatment: Past, Present and Future Aspects.

Authors:  Claire Reid; Christopher E M Griffiths
Journal:  Acta Derm Venereol       Date:  2020-01-30       Impact factor: 3.875

10.  Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.

Authors:  A Blauvelt; C Paul; P van de Kerkhof; R B Warren; A B Gottlieb; R G Langley; F Brock; C Arendt; M Boehnlein; M Lebwohl; K Reich
Journal:  Br J Dermatol       Date:  2020-09-06       Impact factor: 9.302
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.